Synthetic Biology
Home / Services / By Technology / Protein Engineering Services / Protein Modification and Labeling Services / Protein PEGylation / Therapeutic Protein PEGylation Services / PEGylation Services for Cytokines and Enzymes
Trusted by Leading Research & Pharma Institutions

Custom PEG-Cytokines & Enzymes Services

Site-specific PEGylation for enhanced stability, extended half-life, and reduced immunogenicity. Transform your cytokines and enzymes into long-acting biotherapeutics with precision engineering.

>95% Purity
Site-Specific
5-40 kDa PEG
Learn More

Trusted by leading research and pharmaceutical institutions

Harvard
Pfizer
MIT
Roche
Stanford
Novartis

Why Choose Us

Site-specific precision
>90% activity retention
10-50x half-life extension
Complete characterization

Site-Specific Precision

Active site avoidance for maximum retention

Activity-First Approach

Rigorous bioactivity validation

Defined Homogeneity

Batch-to-batch consistency

Market CAGR
12.5%
Overview Technology Specifications Workflow Applications FAQ
Service Overview

Custom PEG-Cytokines and Enzymes Services

Site-specific PEGylation for enhanced stability, extended half-life, and reduced immunogenicity. Transform your cytokines and enzymes into long-acting biotherapeutics with precision engineering.

Site-Specific Precision

Computational modeling identifies optimal PEG attachment sites distant from active sites, ensuring maximum biological activity retention while achieving superior half-life extension.

  • Active site mapping and avoidance
  • Computational site prediction
  • Preserved receptor binding

Activity-First Approach

Our protocols are designed specifically to preserve enzyme catalytic efficiency and cytokine signaling potency. Every modification is validated through rigorous bioactivity assays.

  • >90% activity retention typical
  • Comparative potency assays
  • Structure-function correlation

Extended Half-Life

Strategic PEG architecture pushes hydrodynamic volume above renal filtration threshold for 10-50x half-life extension.

Reduced Immunogenicity

PEG shell masks antigenic determinants, minimizing anti-drug antibody formation and infusion reactions.

Defined Homogeneity

Eliminating positional isomers and batch-to-batch variation with site-specific conjugation for consistent product quality.

Ready to Transform Your Cytokines or Enzymes?

Get a customized quote for your PEGylation project.

Technology Platform

Advanced PEGylation Technology Platform

Multiple conjugation strategies for precise modification of cytokines and enzymes.

N-Terminal Specific PEGylation

Exploiting pKa differences to target the protein N-terminus, preserving lysine side chains and maintaining native orientation for optimal receptor binding.

>80% Selectivity pH Optimized

Cysteine-Specific PEGylation

Using maleimide or iodoacetyl chemistry to target natural or engineered free thiols with high regioselectivity and minimal side reactions.

>95% Selectivity Stable Linkage

Enzymatic Site-Specific PEGylation

Leveraging transglutaminase or sortase enzymes to attach PEG to defined peptide motifs with high accuracy and excellent biocompatibility.

100% Accuracy Mild Conditions

PEG Architecture Options

Linear 5-20 kDa for moderate half-life extension
Y-Branch 40 kDa for superior shielding effect
Multi-Arm 4-arm or 8-arm for maximum protection
Cleavable pH-sensitive or enzyme-cleavable options

PEG Chemistry Options

NHS-Ester Primary amines on lysine residues
Maleimide Thiol groups at pH 6.5-7.5
Aldehyde Reductive amination at N-terminus
Click CuAAC or SPAAC bioorthogonal
Specifications

Service Specifications

Custom PEG-Cytokines / Enzymes service providing comprehensive solutions for therapeutic development needs.

Parameter Specification
Purity >95% (SEC-HPLC verified)
PEG Molecular Weight 5 kDa to 40 kDa (linear, Y-branch, multi-arm)
Conjugation Chemistry NHS-ester, Maleimide, Aldehyde, Enzymatic, Click Chemistry
Activity Retention >90% typical
Half-Life Extension 10-50x typical
Endotoxin <30 EU/mg (or customer specification)
Quality Documentation COA, MS Report, Peptide Mapping, SDS-PAGE, HPLC
Activity Verification Comparative potency assays included
Workflow

Rigorous Four-Phase Workflow

From computational design to functional validation, our streamlined process ensures quality at every step.

1

Computational Design

Structural analysis and site prediction

2

Site-Specific Conjugation

Optimized reaction conditions

3

High-Resolution Purification

Multi-stage chromatography

4

Functional Validation

Bioactivity and stability testing

Applications

Therapeutic Applications

PEGylation enhances cytokine and enzyme therapeutics across multiple therapeutic areas.

Cancer Immunotherapy

PEGylated cytokines and enzymes offer enhanced tumor accumulation and reduced systemic toxicity for cancer immunotherapy applications. Extended half-life enables better tumor penetration and sustained immune activation.

  • PEGylated interleukins (IL-2, IL-15, IL-10)
  • Extended half-life interferons
  • Long-acting cytokine conjugates
  • Tumor-targeting enzyme prodrug systems
10-50x
Half-life Extension

Inflammatory & Autoimmune Diseases

PEGylated anti-inflammatory cytokines offer improved pharmacokinetics for chronic inflammatory disease management. Treg-selective IL-2 variants enable precision immune tolerance induction.

  • Treg-selective IL-2 variants
  • Anti-inflammatory cytokines with enhanced stability
  • Immunomodulators with sustained effects
  • Reduced dosing frequency
Weekly
Dosing Enabled

Enzyme Replacement Therapy

PEGylated enzymes are used for treating lysosomal storage disorders, metabolic conditions, and cancer. Reduced immunogenicity with preserved catalytic activity enables improved therapeutic outcomes.

  • Uricase for gout treatment
  • Asparaginase for ALL therapy
  • Lysosomal enzymes for storage diseases
  • Superoxide dismutase and catalase
>90%
Activity Retention
Testimonials

What Our Partners Say

Trusted by researchers worldwide for quality and reliability.

The site-specific PEGylation strategy they developed preserved over 90% of our cytokine's bioactivity while extending half-life by 10-fold. Their computational modeling expertise is unmatched.

R
Research Scientist
Biotechnology Company

The homogeneity and batch-to-batch consistency of their PEGylated enzymes exceeded our expectations. This level of quality is essential for our IND filing.

P
Principal Scientist
Pharmaceutical Company

Their team handled our multimeric enzyme complex with remarkable expertise. The quaternary structure integrity was fully preserved throughout the PEGylation process.

L
Principal Investigator
Academic Research Institution
Scientific Literature

Supporting Research

Our platform is backed by peer-reviewed research.

128 Citations

PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information

Turecek PL, Bossard MJ, Schoetens F, Ivens IA. Journal of Pharmaceutical Sciences. 2016.

Comprehensive review of PEGylation chemistry and safety data for approved PEGylated drugs.

View DOI
15 Citations

Advances in engineering and delivery strategies for cytokine immunotherapy

Bohmer N, Xue Y, Jankovic K, Dong Y. Expert Opinion on Drug Delivery. 2023.

Review of PEGylation strategies for cytokine immunotherapy including PEGylated interferons and interleukins.

View DOI
8 Citations

The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in inflammatory skin diseases

Silverberg JI, Rosmarin D, Chovatiya R, et al. Nature Communications. 2024.

Clinical results of PEGylated IL-2 agonist in atopic dermatitis and psoriasis.

View DOI
3 Citations

Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing granulocytopenia

Li F, Ye T, Wang Z, et al. Journal of Clinical Oncology. 2023.

Clinical comparison of PEGylated and non-PEGylated G-CSF for chemotherapy-induced neutropenia.

View DOI
45 Citations

PEGylation of Insulin and Lysozyme To Stabilize against Thermal Denaturation: A Molecular Dynamics Simulation Study

Jia Y, Fernandez A, Sampath J. The Journal of Physical Chemistry B. 2023.

Molecular dynamics study showing PEG preserves protein native structure at elevated temperatures by blocking water from hydrophobic cores.

View DOI
FAQ

Frequently Asked Questions

What cytokines and enzymes can be PEGylated?
We work with a wide range of cytokines including interleukins (IL-2, IL-10, IL-15), interferons (IFN-alpha, IFN-beta), TNF variants, G-CSF, and growth factors. For enzymes, we handle uricase, asparaginase, superoxide dismutase, catalase, and other therapeutic enzymes. Each protein requires individual assessment for optimal PEGylation strategy.
How do you preserve cytokine/ enzyme activity during PEGylation?
Our activity-first approach uses computational modeling to identify optimal PEG attachment sites distant from active sites and receptor-binding domains. We validate every conjugate with comparative potency assays to ensure >90% activity retention. Mild reaction conditions and optimized buffer systems minimize protein denaturation.
What PEG size is optimal for cytokine half-life extension?
PEG size selection depends on the target indication and desired half-life extension. For moderate extension (5-10x), 5-10 kDa linear PEG is often sufficient. For dramatic extension (20-50x), larger sizes (20-40 kDa) or branched architectures (Y-shape) are more effective. We optimize based on your specific requirements.
Can you handle multimeric enzyme complexes?
Yes, we have extensive experience with multimeric enzyme complexes. Our protocols are designed to preserve quaternary structure integrity throughout the PEGylation process. We use gentle reaction conditions and careful buffer optimization to maintain the functional assembly of multimeric proteins.
What characterization is included for cytokine/ enzyme conjugates?
Every project includes comprehensive characterization: intact mass analysis by LC-MS, peptide mapping for site determination, SEC-HPLC for purity and aggregation, LC-MS/MS for site occupancy verification, functional potency assays (cell-based), and stability testing. We provide complete documentation packages suitable for regulatory submissions.
What is the typical turnaround time?
Standard projects are completed within 10-14 weeks including computational design, feasibility studies, conjugation optimization, and comprehensive characterization. Complex projects involving novel proteins or extensive optimization may require additional time.
Do you offer GMP manufacturing for clinical trials?
Yes, we offer GMP-compatible manufacturing services for clinical trial material. Our facilities support production at scales suitable for preclinical studies through Phase I/II trials. Complete regulatory documentation packages are provided for IND/CTA submissions.
What PEG architectures do you recommend for cytokines?
The optimal architecture depends on the cytokine and therapeutic goals. Linear PEGs (5-20 kDa) are suitable when minimal steric hindrance is critical. Y-shaped PEGs (40 kDa) provide superior shielding for small cytokines. Multi-arm PEGs offer maximum protection and are ideal for creating high-density functionalized conjugates.
Can you develop cleavable PEG linkers for controlled release?
Yes, we offer intelligent linker technologies including pH-sensitive linkers (hydrazone) for tumor microenvironment activation, disulfide linkers for intracellular reductive environments, and protease-sensitive sequences (MMP-cleavable, cathepsin-sensitive) for tumor-specific release.
How do you handle endotoxin concerns for therapeutic enzymes?
We maintain strict endotoxin control throughout the process. Starting materials are verified for endotoxin levels, and our purification processes include dedicated endotoxin removal steps. Standard specification is less than 30 EU/mg, with lower specifications available upon request.

Ready to Start Your Project?

Get a customized quote for your PEGylation Services for Cytokines and Enzymes project. Our experts will respond within 24 hours.

No obligation
24h response
Expert consultation

Recommended Services

· PEGylation Services for Antibody Fragments (Fab, scFv)

Related Resources

· Cost and Efficiency Analysis of CRlSPR-Cas9 Knockout Services in Mice and Cell Lines
· Validating CRISPR Knockouts: Best Practices for qPCR, Sequencing, and Functional Assays
· Step-by-Step Guide to Generating CRISPR Knockout Cell Lines for Research
Quick Links

Home

Products

Services

About Us

Contact Us

Follow Us
CONTACT US

USA

Tel:

Email:

Japan

Tel:

Email:

Korea

Tel:

Email:

Copyright © 2026 CD Biosynsis. All rights reserved.